Physician profile
Maureen Sarah Burrows
NPI 1518038199
$856.94
in general payments reported to CMS, 2019-2025
13 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Forensic Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $98.51 · 2021: $201 · 2022: $33.50 · 2023: $134 · 2024: $17.13 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $256.09 | 2019-2025 | Rexulti |
| Alkermes, INC. | $133.57 | 2021 | |
| Abbvie INC. | $88.32 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $64.65 | 2019-2025 | |
| Allergan, INC. | $56.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.26 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.68 | 2021-2022 | |
| Lundbeck LLC | $39.33 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $26.82 | 2019 | |
| Supernus Pharmaceuticals, INC. | $26.41 | 2023 | Qelbree |
| Tris Pharma INC | $24.43 | 2023 | Dyanavel Xr |
| Biogen, INC. | $23.55 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $20.89 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.